TY - JOUR
T1 - Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters
AU - Miller, Dennis K.
AU - Crooks, Peter A.
AU - Zheng, Guangrong
AU - Grinevich, Vladimir P.
AU - Norrholm, Seth D.
AU - Dwoskin, Linda P.
PY - 2004/9
Y1 - 2004/9
N2 - Lobeline attenuates the behavioral effects of psychostimulants in rodents and inhibits the function of nicotinic receptors (nAChRs), dopamine transporters (DATs), and vesicular monoamine transporters (VMAT2s). Monoamine transporters are considered valid targets for drug development for the treatment of methamphetamine abuse. In the current study, a series of lobeline analogs were evaluated for affinity and selectivity at these targets. None of the analogs was more potent than nicotine at the [3H]methyllycaconitine binding site (α7* nAChR subtype). Lobeline tosylate was equipotent with lobeline in inhibiting [3H]nicotine binding but 70-fold more potent in inhibiting nicotine-evoked 86Rb+ efflux, demonstrating antagonism of α4β2* nAChRs. Compared with lobeline, the defunctionalized analogs lobelane, mesotransdiene, and (-)-trans-transdiene showed dramatically reduced affinity at α4β2* nAChRs and a 15- to 100-fold higher affinity (KiK = 1.95, 0.58, and 0.26 μM, respectively) at DATs. Mesotransdiene and (-)-transtransdiene competitively inhibited DAT function, whereas lobelane and lobeline acted noncompetitively. 10S/10R-MEPP [N-methyl-2R-(2R/2S-hydroxy-2-phenylethyl)6S-(2-phenylethyl) piperidine] and 10R-MESP [N-methyl-2R-(2R-hydroxy-2-phenylethyl)6S-(2- phenylethen-1-yl)piperidine] were 2 to 3 orders of magnitude more potent (K i = 0.01 and 0.04 μM, respectively) than lobeline in inhibiting [3H]serotonin uptake; 10S/10R-MEPP showed a 600-fold selectivity for this transporter. Uptake results using hDATs and human serotonin transporters expressed in human embryonic kidney-293 cells were consistent with native transporter assays. Lobelane and ketoalkene were 5-fold more potent (K i = 0.92 and 1.35 μM, respectively) than lobeline (Ki = 5.46 μM) in inhibiting [3H]methoxytetrabenazine binding to VMAT2 in vesicle preparations. Thus, structural modification (defunctionalization) of the lobeline molecule markedly decreases affinity for α4β2* and α7* nAChRs while increasing affinity for neurotransmitter transporters, affording analogs with enhanced selectivity for these transporters and providing new leads for the treatment of psychostimulant abuse.
AB - Lobeline attenuates the behavioral effects of psychostimulants in rodents and inhibits the function of nicotinic receptors (nAChRs), dopamine transporters (DATs), and vesicular monoamine transporters (VMAT2s). Monoamine transporters are considered valid targets for drug development for the treatment of methamphetamine abuse. In the current study, a series of lobeline analogs were evaluated for affinity and selectivity at these targets. None of the analogs was more potent than nicotine at the [3H]methyllycaconitine binding site (α7* nAChR subtype). Lobeline tosylate was equipotent with lobeline in inhibiting [3H]nicotine binding but 70-fold more potent in inhibiting nicotine-evoked 86Rb+ efflux, demonstrating antagonism of α4β2* nAChRs. Compared with lobeline, the defunctionalized analogs lobelane, mesotransdiene, and (-)-trans-transdiene showed dramatically reduced affinity at α4β2* nAChRs and a 15- to 100-fold higher affinity (KiK = 1.95, 0.58, and 0.26 μM, respectively) at DATs. Mesotransdiene and (-)-transtransdiene competitively inhibited DAT function, whereas lobelane and lobeline acted noncompetitively. 10S/10R-MEPP [N-methyl-2R-(2R/2S-hydroxy-2-phenylethyl)6S-(2-phenylethyl) piperidine] and 10R-MESP [N-methyl-2R-(2R-hydroxy-2-phenylethyl)6S-(2- phenylethen-1-yl)piperidine] were 2 to 3 orders of magnitude more potent (K i = 0.01 and 0.04 μM, respectively) than lobeline in inhibiting [3H]serotonin uptake; 10S/10R-MEPP showed a 600-fold selectivity for this transporter. Uptake results using hDATs and human serotonin transporters expressed in human embryonic kidney-293 cells were consistent with native transporter assays. Lobelane and ketoalkene were 5-fold more potent (K i = 0.92 and 1.35 μM, respectively) than lobeline (Ki = 5.46 μM) in inhibiting [3H]methoxytetrabenazine binding to VMAT2 in vesicle preparations. Thus, structural modification (defunctionalization) of the lobeline molecule markedly decreases affinity for α4β2* and α7* nAChRs while increasing affinity for neurotransmitter transporters, affording analogs with enhanced selectivity for these transporters and providing new leads for the treatment of psychostimulant abuse.
UR - http://www.scopus.com/inward/record.url?scp=4243079826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4243079826&partnerID=8YFLogxK
U2 - 10.1124/jpet.104.068098
DO - 10.1124/jpet.104.068098
M3 - Article
C2 - 15121762
AN - SCOPUS:4243079826
SN - 0022-3565
VL - 310
SP - 1035
EP - 1045
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 3
ER -